Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?

Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?

Bibliographic Details
Main Authors:	Diego Martin Moreno Marreros, Maycol Leonardo Aburto Moreno, Kattia Gassely Torres Gil, Carlos Morera Guzman
Format:	Article
Language:	English
Published:	The Korean Academy of Tuberculosis and Respiratory Diseases 2021-07-01
Series:	Tuberculosis and Respiratory Diseases
Online Access:	http://e-trd.org/upload/pdf/trd-2021-0081.pdf

Similar Items

Confluence of obesity and MAFLD during Covid‐19 pandemic in a developing country
by: Jhean Gabriel Gonzáles Yovera, et al.
Published: (2021-04-01)

Dexamethasone as a Treatment of COVID-19
by: Abdullah Alkattan, et al.
Published: (2020-12-01)

Dexamethasone and remdesivir: finding method in the COVID-19 madness
by: Pauline Vetter, et al.
Published: (2020-12-01)

Worrying situation regarding the use of dexamethasone for COVID-19
by: Michael Anthonius Lim, et al.
Published: (2020-07-01)

Dexamethasone for treatment of severe COVID-19, a surprise?
by: Hany Hasan Elsayed
Published: (2020-09-01)

DEXAMETHASONE USE IN MANAGEMENT OF COVID19: A REVIEW
by: Samer Mohammed
Published: (2021-03-01)

Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?
by: Vasiliki Romanou, et al.
Published: (2021-06-01)

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
by: Ricardo Águas, et al.
Published: (2021-02-01)

The Appropriate Use of Testing for COVID-19
by: Tony Zitek
Published: (2020-04-01)

The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia
by: Hyun Woo Lee, et al.
Published: (2021-07-01)

Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy
by: Ivan G. Shabalin, et al.
Published: (2020-11-01)

Dexamethasone in severe COVID-19 infection: A case series
by: Mohamed Eliwa Hassan, et al.
Published: (2020-01-01)

Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
by: Claudio Ortolani, et al.
Published: (2020-09-01)

Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom
by: Luigino Calzetta, et al.
Published: (2021-04-01)

Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.
by: Miguel Alejandro Pinzón, et al.
Published: (2021-01-01)

Appropriate use of tocilizumab in COVID-19 infection
by: Şiran Keske, et al.
Published: (2020-10-01)

Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
by: Alexander Hooftman, et al.
Published: (2021-01-01)

The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
by: Heloísa Antoniella Braz-de-Melo, et al.
Published: (2021-04-01)

Author Correction: Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
by: Ricardo Águas, et al.
Published: (2021-03-01)

Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes
by: Janine Alessi, et al.
Published: (2020-09-01)

Is case fatality rate an appropriate index to represent the status of case-finding process for COVID-19 in different countries?
by: Moslem Taheri Soodejani, et al.
Published: (2020-01-01)

Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?
by: Tomoshige Kino, et al.
Published: (2021-06-01)

Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa
by: Helen Brotherton, et al.
Published: (2020-09-01)

Persistent hiccups after treatment of COVID-19 with dexamethasone: A case report
by: Sajad Karampoor, et al.
Published: (2021-01-01)

Immunogenomic phases of COVID-19 and appropriate clinical management
by: Ibrahim C Haznedaroglu
Published: (2020-11-01)

Appropriateness of lung ultrasound for the diagnosis of COVID‐19 pneumonia
by: Zouheir Ibrahim Bitar, et al.
Published: (2021-06-01)

Is a new COVID-19 social contract appropriate?
by: Guy La Ruche, et al.
Published: (2021-06-01)

Is a new COVID-19 social contract appropriate?
by: Cédric Annweiler, et al.
Published: (2021-06-01)

COVID-19 and clinical mimics. Correct diagnosis is the key to appropriate therapy
by: Kamal Kant Sahu, et al.
Published: (2020-05-01)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
by: Zarębska-Michaluk D, et al.
Published: (2021-07-01)

Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap
by: Lucia Gozzo, et al.
Published: (2020-11-01)

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
by: Selçuk Şen, et al.
Published: (2020-10-01)

Algunas reflexiones sobre la COVID-19
by: Álvaro Montero Sánchez, et al.
Published: (2021-07-01)

Impact of dexamethasone use to prevent from severe COVID-19-induced acute kidney injury
by: Arthur Orieux, et al.
Published: (2021-07-01)

Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19
by: O. V. Zhukova, et al.
Published: (2021-04-01)

Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients
by: Armen Oganesyan, et al.
Published: (2021-01-01)

Imaging Appropriateness in Pediatric Radiology during COVID-19 Pandemic: A Retrospective Comparison with No COVID-19 Period
by: Giampiero Bottari, et al.
Published: (2021-06-01)

COVID-19 appropriate behavior in India: Time to invest for the benefits in future
by: Manoj Kumar Gupta, et al.
Published: (2021-01-01)

La cartografía digital generada por la COVID-19: Análisis y tipologías = The digital cartography generated by COVID-19: Analysis and typologies
by: Carlos Guallart Moreno
Published: (2020-10-01)

Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone
by: Chrysi Keskinidou, et al.
Published: (2021-07-01)

Cannot write session to /tmp/vufind_sessions/sess_0solofdim6lsfmkf4r88qmdeiu